Jacobs Levy Equity Management Inc. Purchases 24,000 Shares of Recro Pharma Inc (NASDAQ:REPH)
Jacobs Levy Equity Management Inc. boosted its stake in Recro Pharma Inc (NASDAQ:REPH) by 40.8% during the fourth quarter, HoldingsChannel reports. The firm owned 82,786 shares of the specialty pharmaceutical company’s stock after buying an additional 24,000 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Recro Pharma were worth $1,517,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in REPH. State Street Corp raised its stake in shares of Recro Pharma by 31.2% during the third quarter. State Street Corp now owns 394,904 shares of the specialty pharmaceutical company’s stock worth $4,376,000 after acquiring an additional 93,855 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in Recro Pharma in the fourth quarter valued at $858,000. California State Teachers Retirement System boosted its holdings in Recro Pharma by 2.3% in the third quarter. California State Teachers Retirement System now owns 30,178 shares of the specialty pharmaceutical company’s stock valued at $334,000 after acquiring an additional 688 shares in the last quarter. EAM Investors LLC boosted its holdings in Recro Pharma by 97.0% in the fourth quarter. EAM Investors LLC now owns 160,381 shares of the specialty pharmaceutical company’s stock valued at $2,940,000 after acquiring an additional 78,952 shares in the last quarter. Finally, Calamos Advisors LLC bought a new stake in Recro Pharma in the fourth quarter valued at $3,096,000. 66.97% of the stock is currently owned by institutional investors and hedge funds.
Several analysts recently weighed in on the stock. ValuEngine cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. Stephens dropped their target price on shares of Recro Pharma from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Finally, BidaskClub cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $17.67.
Recro Pharma (NASDAQ:REPH) last announced its earnings results on Wednesday, March 4th. The specialty pharmaceutical company reported $0.61 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.91. Recro Pharma had a negative net margin of 18.78% and a negative return on equity of 28.76%. Equities research analysts expect that Recro Pharma Inc will post 0.53 earnings per share for the current year.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Read More: How a Back-End Load Mutual Fund Works
Want to see what other hedge funds are holding REPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recro Pharma Inc (NASDAQ:REPH).
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.